.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,407,955

« Back to Dashboard

Claims for Patent: 7,407,955

Title:8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Abstract:The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Inventor(s): Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Warthausen, DE), Eckhardt; Matthias (Biberach, DE), Mark; Michael (Biberach, DE), Maier; Roland (Biberach, DE), Lotz; Ralf R. H. (Schemmerhofen, DE), Tadayyon; Mohammad (Ulm, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)
Application Number:10/639,036
Patent Claims: 1. A compound chosen from: (1) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-pipe- ridin-1-yl)-xanthine, (2) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-- butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (3) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2- -butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (4) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-pip- eridin-1-yl)-xanthine, (5) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-- amino-piperidin-1-yl)-xanthine, (6) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-- amino-piperidin-1-yl)-xanthine, (7) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-- amino-piperidin-1-yl)-xanthine, (8) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-- amino-piperidin-1-yl)-xanthine, (9) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn- -1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, (10) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-- amino-piperidin-1-yl)-xanthine, (11)-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)- -3-amino-piperidin-1-yl)-xanthine, (12) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R- )-3-amino-piperidin-1-yl)-xanthine, (13) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine, (14) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((- E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (15) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((- E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (16) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-but- yn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (17) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-am- ino-piperidin-1-yl)-xanthine, (18) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (19) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (20) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (21) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amin- o-piperidin-1-yl)-xanthine, (22) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-- 8-((R)-3-amino-piperidin-1-yl)-xanthine, (23) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8- -((R)-3-amino-piperidin-1-yl)-xanthine, (24) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amin- o-piperidin-1-yl)-xanthine, (25) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((- R)-3-amino-piperidin-1-yl)-xanthine, (26) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (27) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)- -3-amino-piperidin-1-yl)-xanthine and (28) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-- 3-amino-piperidin-1-yl)-xanthine or tautomers, enantiomers, diastereomers, mixtures thereof or salts thereof.

2. A compound chosen from: (1) 1-(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-- xanthine, (2) 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (3) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (4) 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-me- thyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (5) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (6) 1-(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl- )-xanthine, (7) 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1- -yl)-xanthine, (8) 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (9) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3- -methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (10) 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-- (3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (11) 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl- )-xanthine, (12) 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-amino-piperi- din-1-yl)-xanthine, (13) 1-methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xant- hine, (14) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperi- din-1-yl)-xanthine, (15)-{2-[3-(2-oxo-imidazolidin-1-yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-m- ethyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (16) 1-methyl-3-(2-propen-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-- xanthine, (17) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-- 2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (18) 1-methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, (19) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl- )-8-((S)-3-amino-piperidin-1-yl)-xanthine, (20) 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1-yl)-8-(3-ami- no-piperidin-1-yl)-xanthine, (21) 1-[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (22) 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (23) 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (24) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl- -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (25) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-bute- n-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (26) 1-[(quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino- -piperidin-1-yl)-xanthine, (27) 1-[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (28) 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amin- o-piperidin-1-yl)-xanthine, (29) 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1- -yl)-8-(3-amino-piperidin-1-yl)-xanthine, (30) 1-[(4-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (31) 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (32) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (33) 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (34) 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-bute- n-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (35) 1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-bute- n-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (36) 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8- -(3-amino-piperidin-1-yl)-xanthine, (37) 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (38)-{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (39) 1-{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl- -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (40) 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (41) 1-[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8- -(3-amino-piperidin-1-yl)-xanthine, (42) 1-[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (43) 1-{2-[2-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl- -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (44) 1-{2-[2-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (45) 1-[2-(2,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-y- l)-8-(3-amino-piperidin-1-yl)-xanthine, (46) 1-((E)-3-phenyl-allyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-pipe- ridin-1-yl)-xanthine, (47) 1-[(benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (48) 1-[(1H-indol-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (49) 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (50) 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amin- o-piperidin-1-yl)-xanthine, (51) 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amin- o-piperidin-1-yl)-xanthine, (52) 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-- (3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (53) 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-a- mino-piperidin-1-yl)-xanthine, (54) 1-[2-(piperidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(- 3-amino-piperidin-1-yl)-xanthine, (55) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-but- en-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (56) 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-y- l)-8-(3-amino-piperidin-1-yl)-xanthine, (57) 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-- (3-amino-piperidin-1-yl)-xanthine, (58) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (59) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-- 7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (60) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-- yl)-8-(3-amino-piperidin-1-yl)-xanthine, (61) 1-methyl-3-isopropyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthi- ne, (62) 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (63) 1-[(isoquinolin-1-yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-bu- ten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (64) 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(- 3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (65) 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-met- hyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (66) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-y- l)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (67) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3- -methyl-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (68) 1-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, (69) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-met- hyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (70) 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (71) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-- 7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (72) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (73) 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (74) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-- 8-((R)-3-amino-piperidin-1-yl)-xanthine, (75) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3-am- ino-piperidin-1-yl)-xanthine, (76) 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine and (77) 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, or tautomers, enantiomers, diastereomers, mixtures thereof or the salts thereof.

3. A physiologically acceptable salt of a compound according to claim 1 or 2 with an inorganic or organic acid or base.

4. A pharmaceutical composition comprising a pharmaceutically acceptable amount of a compound according to claim 1 or 3 optionally together with one or more inert carriers and/or diluents.

5. A compound of formula (I) ##STR00006## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl.

6. A pharmaceutical composition comprising one or more inert carriers or diluents and a compound of formula (I) ##STR00007## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl.

7. A salt of a compound of formula (I) ##STR00008## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl.

8. A physiologically acceptable salt of a compound of formula (I) ##STR00009## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl.

9. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of a compound of formula (I) ##STR00010## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl.

10. A salt of a compound of formula (I) ##STR00011## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl, with an inorganic or organic acid.

11. A physiologically acceptable salt of a compound of formula (I) ##STR00012## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl, with an inorganic or organic acid.

12. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of a compound of formula (I) ##STR00013## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl, with an inorganic or organic acid.

13. The compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00014##

14. A pharmaceutical composition comprising one or more inert carriers or diluents and the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00015##

15. A salt of the compound 1[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00016##

16. A physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00017##

17. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00018##

18. A salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl-xanthine of the formula ##STR00019## with an inorganic or organic acid.

19. A physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00020## with an inorganic or organic acid.

20. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00021## with an inorganic or organic acid.

21. A pharmaceutical composition comprising a pharmaceutically acceptable amount of a physiologically acceptable salt according to claim 3, optionally together with one or more inert carriers and/or diluents.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc